Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases-Reference-Cited by-同舟云学术

Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases

Published:2018-01-02 Issue:1 Volume:9 Page:28-33
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Michaelides Michael R.¹^ORCID,Kluge Arthur²,Patane Michael²,Van Drie John H.²,Wang Ce³,Hansen T. Matthew¹,Risi Roberto M.¹,Mantei Robert¹,Hertel Carmen²,Karukurichi Kannan²,Nesterov Alexandre²,McElligott David²,de Vries Peter²,Langston J. William²,Cole Philip A.²,Marmorstein Ronen²,Liu Hong¹,Lasko Loren¹,Bromberg Kenneth D.¹,Lai Albert¹,Kesicki Edward A.²

Affiliation:

1. AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States

2. Acylin Therapeutics, Inc., 1616 Eastlake Avenue E, Suite 200, Seattle, Washington 98012, United States

3. BioDuro, No. 29 Life Science Park Road, Changping District, Beijing 102206, P. R. China

Funder

AbbVie

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

http://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.7b00395